Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
May 20, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
May 13, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment
May 07, 2020 09:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs
May 07, 2020 08:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study
April 27, 2020 08:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 27, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
April 20, 2020 08:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19...
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
April 16, 2020 08:00 ET
|
Atossa Therapeutics, Inc.
SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...